MALAT1 and breast carcinoma: A different effect was reported forthe metastasis-free survival rate of breast cancer patients: the decreasedMALAT1 expression in these patients was associated with worse survival rates(HR = 0.81; 95% CI 0.67–0.99, p = 0.0420; HR = 0.65; 95%CI, p = 0.005) [23].However, in this case, the conclusion was based on experimental resultsdemonstrating that MALAT1 acts as an EMT inducer in breast cancer patients byactivating the PI3K-Akt pathway.